clinical trial · NCT04661007
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Incyte Biosciences Japan GK·phase2·active not recruiting·n = 72
Non Hodgkins LymphomaDiffuse Large B-cell LymphomatafasitamablenalidomideparsaclisibR-CHOP
brief summary
This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.
started
Dec 15, 2020
primary completion
Jul 1, 2025
completion
Dec 31, 2026
last updated
May 18, 2026
official title
A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol